Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.

[2] Anrukinzumab was developed by Wyeth.

Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.